efficacy and safety of Gemcitabine plus nab-paclitaxel in unresectable pancreas cancer
Not Applicable
- Conditions
- unresectable pancreas cancer
- Registration Number
- JPRN-UMIN000013206
- Lead Sponsor
- Yokohama City University Hospital Oncology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 0
Inclusion Criteria
Not provided
Exclusion Criteria
other malignant diseases Paformance status 3,4 uncontrolable pleural effusion and/or ascites uncontrolable infection uncontrolable DM past treatment history to pancreas cancer
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method response rate
- Secondary Outcome Measures
Name Time Method progression free survival overall survival classification of elastography
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms explain Gemcitabine/nab-paclitaxel synergy in unresectable pancreatic ductal adenocarcinoma?
How does Gemcitabine plus nab-paclitaxel compare to FOLFIRINOX in JPRN-UMIN000013206 for advanced pancreas cancer outcomes?
Which biomarkers correlate with response to nab-paclitaxel/Gemcitabine in KRAS-mutant unresectable pancreatic tumors?
What are the most common adverse events in JPRN-UMIN000013206 Gemcitabine/nab-paclitaxel treatment and mitigation strategies?
Are there emerging taxane-based combinations rivaling Gemcitabine plus nab-paclitaxel for metastatic pancreatic cancer therapy?